AMRN | Amarin Corporation plc

Healthcare | Drug Manufacturers - General | Ireland | NASD

Index	-	P/E	-	EPS (ttm)	-0.23	Insider Own	0.30%	Shs Outstand	406.18M	Perf Week	-1.56%
Market Cap	503.60M	Forward P/E	-	EPS next Y	-0.14	Insider Trans	0.00%	Shs Float	361.03M	Perf Month	-0.79%
Income	-90.70M	PEG	-	EPS next Q	-0.03	Inst Own	32.70%	Short Float / Ratio	5.81% / 7.78	Perf Quarter	-20.75%
Sales	360.50M	P/S	1.40	EPS this Y	34.60%	Inst Trans	-7.43%	Short Interest	20.98M	Perf Half Y	7.69%
Book/sh	1.44	P/B	0.87	EPS next Y	17.60%	ROA	-10.00%	Target Price	2.12	Perf Year	-33.33%
Cash/sh	0.76	P/C	1.65	EPS next 5Y	38.90%	ROE	-15.50%	52W Range	1.04 - 2.23	Perf YTD	4.13%
Dividend	-	P/FCF	-	EPS past 5Y	-3.40%	ROI	-18.10%	52W High	-43.50%	Beta	1.78
Dividend %	-	Quick Ratio	1.90	Sales past 5Y	15.30%	Gross Margin	68.90%	52W Low	21.15%	ATR	0.07
Employees	365	Current Ratio	2.80	Sales Q/Q	-9.10%	Oper. Margin	-26.30%	RSI (14)	47.86	Volatility	4.75% 6.08%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	48.90%	Profit Margin	-25.20%	Rel Volume	0.34	Prev Close	1.30
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 03 BMO	Payout	-	Avg Volume	2.70M	Price	1.26
Recom	2.80	SMA20	0.80%	SMA50	-5.05%	SMA200	-10.13%	Volume	910,216	Change	-3.08%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-06-23	Upgrade	Jefferies	Hold → Buy	$1.30 → $3
May-06-22	Downgrade	JP Morgan	Neutral → Underweight
May-05-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10 → $3
May-05-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $3
May-04-22	Downgrade	Northland Capital	Outperform → Market Perform
May-12-21	Downgrade	Goldman	Neutral → Sell	$6 → $5
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-26-20	Initiated	Piper Sandler	Overweight	$21
May-05-20	Initiated	Northland Capital	Outperform	$15
Mar-31-20	Upgrade	Oppenheimer	Underperform → Perform
Mar-31-20	Downgrade	Jefferies	Buy → Hold	$30 → $4
Mar-31-20	Downgrade	Goldman	Buy → Neutral
Mar-13-20	Upgrade	Goldman	Neutral → Buy	$28
Mar-02-20	Initiated	Cowen	Outperform	$23
Feb-18-20	Upgrade	Citigroup	Neutral → Buy	$27 → $24
Jan-06-20	Initiated	JP Morgan	Neutral	$22
Dec-16-19	Downgrade	Stifel	Buy → Hold
Nov-20-19	Initiated	Oppenheimer	Underperform	$7
Nov-18-19	Downgrade	Citigroup	Buy → Neutral
Nov-15-19	Reiterated	SVB Leerink	Outperform	$26 → $29

Show Previous Ratings

Jun-08-23 11:07AM	Investors Aren't Buying Amarin Corporation plc's (NASDAQ:AMRN) Revenues (Simply Wall St.)
Jun-01-23 04:30PM	Amarin to Present at Two Upcoming Investor Conferences (GlobeNewswire)
06:00AM	Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China (GlobeNewswire)
May-23-23 09:50AM	3 Biotech Stocks to Avoid Like the Plague (InvestorPlace)
May-12-23 11:00AM	Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events (GlobeNewswire)
02:00PM	Loading…
May-03-23 02:00PM	Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript (Motley Fool)
01:47PM	Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall (Zacks)
07:41AM	Amarin: Q1 Earnings Snapshot (AP Finance)
07:00AM	Amarin Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-02-23 01:32PM	Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More (Zacks)
Apr-19-23 08:00AM	Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 (GlobeNewswire)
Apr-17-23 07:00AM	Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver OConnor to Companys Board of Directors (GlobeNewswire)
Apr-13-23 10:18AM	Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation (Simply Wall St.)
Apr-12-23 09:18AM	Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock? (Zacks)
Apr-04-23 03:53PM	Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today (Motley Fool)
08:00AM	Loading…
08:00AM	Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health (GlobeNewswire)
Mar-16-23 08:00AM	Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl) (GlobeNewswire) +7.24%
Mar-06-23 04:05PM	Amarin Announces Board Departures (GlobeNewswire)
09:37AM	Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome (Benzinga)
08:00AM	Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC (GlobeNewswire)
Mar-05-23 10:21AM	Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event (GlobeNewswire)
Mar-03-23 11:09AM	Amarin Corporation plc (NASDAQ:AMRN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-02-23 01:23PM	Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates (Zacks) -5.34%
11:44AM	Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales (Zacks)
05:55AM	Amarin Full Year 2022 Earnings: US$0.26 loss per share (vs US$0.02 profit in FY 2021) (Simply Wall St.)
Mar-01-23 11:02AM	Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up (Zacks)
11:00AM	Amarin Plc (AMRN) Q4 2022 Earnings Call Transcript (Motley Fool)
07:00AM	Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-23 11:11AM	Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales (Zacks) +10.33%
10:39AM	Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide (Business Wire)
10:38AM	Loading…
10:38AM	Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders (GlobeNewswire)
08:00AM	Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand (GlobeNewswire)
Feb-27-23 04:29PM	Amarin Sets the Record Straight on Sarissas Latest Misstatements (GlobeNewswire)
08:00AM	Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC (GlobeNewswire)
07:15AM	Sarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives (Business Wire)
Feb-24-23 11:52AM	Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4 (Zacks)
Feb-22-23 04:50PM	Hikma accuses Amarin of suppressing generic versions of heart pill (Reuters)
08:00AM	Amarin to Present at Cowen's 43rd Annual Health Care Conference (GlobeNewswire)
Feb-21-23 08:30AM	Sarissa Capital Reminds Amarin Shareholders Today Is the Last Day to Vote "FOR" Change (Business Wire)
08:00AM	Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023 (GlobeNewswire)
Feb-20-23 01:00PM	Sarissa Capital Urges Amarin Shareholders to Vote "FOR" Necessary Change (Business Wire)
Feb-17-23 09:03AM	Amarin Urges Shareholders to Vote Against Sarissas Harmful Proposals at Upcoming General Meeting IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE (GlobeNewswire)
07:30AM	Sarissa Capital Urges Amarin Shareholders to Vote for Change and Remake Amarin for Shareholders (Business Wire)
Feb-16-23 04:05PM	Sarissa Capital Blasts Amarins Repeated False Statements; Clearly Amarin Will Say Anything to Keep Sarissa Off the Board (Business Wire)
12:34PM	Leading Independent Proxy Firm ISS Joins Glass Lewis in Recommending that Amarin Shareholders Vote AGAINST Sarissas Value-Destructive Proposals (GlobeNewswire)
09:44AM	Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards (GlobeNewswire)
Feb-15-23 04:29PM	Sarissa Capital Uncovers That Amarins Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So (Business Wire)
Feb-14-23 05:09PM	Sarissa Capital Disappointed That Amarin Webcast Continues Boards Defense of Poor Results and Lack of Accountability (Business Wire)
09:55AM	Amarin (AMRN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Feb-13-23 07:47PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote AGAINST All of Sarissas Proposals (GlobeNewswire)
09:40AM	Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:00AM	Sarissa Capital Warns of Amarins Expensive Attempts to Switch Votes by Inundating Shareholders With White Proxy Cards (Business Wire)
08:00AM	Amarin Shareholders Invited to Webcast with Board and Management Team (GlobeNewswire)
Feb-09-23 05:27PM	Sarissa Capital Does Not Believe Amarin Cares About Shareholders (Business Wire)
08:00AM	Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card AGAINST Sarissas Harmful Proposals (GlobeNewswire)
Feb-07-23 04:35PM	Sarissa Capital Highlights Amarins Inaccurate and Misleading Statements (Business Wire) +12.89%
Feb-06-23 08:00AM	Amarin Mails Letter to Shareholders Highlighting Sarissas Myths vs. The Facts (GlobeNewswire)
Feb-03-23 05:16PM	Sarissa Capital Highlights Amarins Disregard for Shareholder Interests and Urges Shareholders to Vote the BLUE Proxy Card for Change at Amarin (Business Wire)
Feb-02-23 04:30PM	Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership (GlobeNewswire)
Feb-01-23 04:09PM	Sarissa Capital Urges Amarin Shareholders to Vote the Blue Card by February 22 to Fix Amarin for the Benefit of Shareholders (Business Wire)
Jan-31-23 08:24AM	Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders (GlobeNewswire)
Jan-27-23 06:35PM	Amarin and ViewRay Stock See Action From Activist Investors (Barrons.com)
08:45AM	Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand (GlobeNewswire)
08:00AM	Amarin to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-23-23 11:01AM	Amarin Corporation (AMRN) Down 13% in One Week: Here's Why (Zacks)
Jan-20-23 10:04AM	Why Amarin Stock Tumbled This Week (Motley Fool)
Jan-19-23 09:15PM	3 Penny Stocks to Sell in January Before They Peter Out (InvestorPlace)
12:04PM	Amarin Calls Activist Investor, Largest Shareholder Sarissa's Statement 'Inaccurate, Misleading' (Benzinga)
07:00AM	Amarin Responds to Inaccurate and Misleading Statement by Sarissa (GlobeNewswire)
Jan-18-23 11:11AM	2 Momentum Trades Showing Worst to First Action (TheStreet.com) -6.09%
07:30AM	Sarissa Capital Calls Out Amarins Sham Board Refreshment (Business Wire)
Jan-14-23 08:46AM	Strong week for Amarin (NASDAQ:AMRN) shareholders doesn't alleviate pain of three-year loss (Simply Wall St.)
Jan-11-23 07:14PM	Amarin's (AMRN) Q4 Preliminary Revenues Top Expectations (Zacks) +5.81%
04:33PM	Amarin Comments on Sarissas Notice to Call a Special Meeting of Amarin Shareholders (GlobeNewswire)
Jan-10-23 01:34PM	Sarissa Capital Submits Notice to Call a Special Meeting of Amarin Shareholders to Add Directors and Remove Chairman Per Wold-Olsen (Business Wire) +16.22%
12:40PM	Amarins stock is up 17% on strong revenue estimates for 2022 (MarketWatch)
07:15AM	Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023 (GlobeNewswire)
07:00AM	Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP (GlobeNewswire)
Dec-14-22 07:00AM	Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-22 08:30AM	Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland (GlobeNewswire)
Nov-21-22 08:42AM	Why Amarin (AMRN) Stock Might be a Great Pick (Zacks)
Nov-15-22 05:53PM	Why Amarin Stock Was a Winner Today (Motley Fool)
07:00AM	Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia (GlobeNewswire)
Nov-09-22 08:00AM	Amarin to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-22 08:00AM	Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care (GlobeNewswire) +11.97%
Nov-04-22 08:58AM	Here's Why We're Watching Amarin's (NASDAQ:AMRN) Cash Burn Situation (Simply Wall St.)
Oct-28-22 12:02PM	Amarin (AMRN) Q3 Earnings Beat, Sales Hurt by Vascepa Generics (Zacks) +7.89%
Oct-27-22 03:30PM	Amarin (AMRN) Q3 2022 Earnings Call Transcript (Motley Fool)
07:00AM	Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-20-22 04:30PM	Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors (GlobeNewswire)
11:48AM	Zymeworks Inc. (ZYME) Surges 15.9%: Is This an Indication of Further Gains? (Zacks)
08:00AM	Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022 (GlobeNewswire)
Oct-11-22 04:15PM	Amarin Board of Directors Issues Statement in Response to Sarissa (GlobeNewswire)
07:30AM	Sarissa Capital Has Commenced the Process to Call a Special Meeting of Amarin Shareholders to Remove and Replace Certain Board Members (Business Wire)
Aug-30-22 08:00AM	Amarin to Present at H.C. Wainwrights 24th Annual Global Investment Conference (GlobeNewswire)
Aug-29-22 07:16AM	Amarin Touts Positive Data For Its Heart Disease Drug In Current/Former Smokers (Benzinga)
Aug-28-22 05:51AM	New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers (GlobeNewswire)
Aug-26-22 12:08PM	Amarin's New Vascepa Data Shows Significant Reduction In Heart Attack Subtypes (Benzinga)
09:17AM	Why Amarin Stock Was Plunging This Week (Motley Fool)
08:19AM	New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes (GlobeNewswire)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WOLD OLSEN PER	Director	Jun 13	Buy	1.69	55,000	92,730	149,000	Jun 15 08:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMRN | Amarin Corporation plc

Upgrade your FINVIZ experience